Nitrogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/357)
  • Patent number: 6720315
    Abstract: The present invention relates to a class of compounds represented by the Formula 1. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: April 13, 2004
    Assignee: Pharmacia Corporation
    Inventors: Thomas Rogers, Michael Clare, Hwang-Fun Lu, Mark Russell, James W. Malecha, Ish Kumar Khanna, Thomas Penning, Srinivasan Raj Nagarajan, Heather Stenmark
  • Publication number: 20040067988
    Abstract: This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 8, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Scott I. Klein, Kevin R. Guertin
  • Publication number: 20040067927
    Abstract: The invention relates to novel compounds which are substituted alkyldiamino derivatives of formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I) and especially their use as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 8, 2004
    Inventors: Christoph Boss, Walter Fischli, Solange Meyer, Sylvia Richard-Bildstein, Thomas Weller
  • Publication number: 20040067987
    Abstract: Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer's Disease and diabetes.
    Type: Application
    Filed: March 11, 2003
    Publication date: April 8, 2004
    Applicant: MitoKor
    Inventors: Soumitra S. Ghosh, Tomas R. Szabo
  • Patent number: 6716457
    Abstract: The present invention relates to a process for inhibiting or eliminating the growth of microorganisms in pesticide suspensions. More particularly, the process of the present invention includes the addition of a combination of peracetic acid, hydrogen peroxide, and water to the pesticide suspension. Further, the process of the present invention includes the application of the peracetic acid, hydrogen peroxide, and water combination to the interior surface of the vessel in which the pesticide suspension is contained. Still further, the process of the present invention includes the application of the peracetic acid, hydrogen peroxide, and water combination to a surface in which the pesticide suspension is in contact.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: April 6, 2004
    Assignee: Bayer Polymers LLC
    Inventors: Karen L. Eagles, Donald W. Edson, Kevin Park, John G. Rogers, John W. Brandriff, Stephen C. Slahck
  • Patent number: 6716818
    Abstract: The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R1-R3, X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Eckard Weber, Yan Wang, Gordon B Mills, Douglas R Green
  • Publication number: 20040063781
    Abstract: 1
    Type: Application
    Filed: October 14, 2003
    Publication date: April 1, 2004
    Inventors: Benjamin Pelcman, Annika Gustafsson, Philip R Kym
  • Publication number: 20040063643
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: April 28, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Michael Higginbottom, Suzanne Ross Kesten, Russell Andrew Lewthwaite, Martyn Clive Pritchard, David James Rawson, Robert Michael Schelkun, Po-Wai Yuen
  • Publication number: 20040063672
    Abstract: The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EDF receptor kinase inhibitor.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Inventors: Philip Frost, Jeremy I. Levin
  • Publication number: 20040063766
    Abstract: The invention relates to the use of aminoacetonitrile compounds of formula 1
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Inventors: Pierre Ducray, Jacques Bouvier
  • Publication number: 20040058962
    Abstract: Described are novel substituted phenylalkylamines and pyridylalkylamines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri
  • Publication number: 20040058968
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: July 11, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Publication number: 20040053977
    Abstract: Compounds having a structure according to Formula (I): 1
    Type: Application
    Filed: September 12, 2003
    Publication date: March 18, 2004
    Inventors: Ji-In Kim Almstead, Nicholas John Izzo, David Robert Jones, Richard Masaru Kawamoto
  • Publication number: 20040053953
    Abstract: Methods of treating chemokine-mediated diseases are disclosed.
    Type: Application
    Filed: March 17, 2003
    Publication date: March 18, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
  • Publication number: 20040053976
    Abstract: The present invention is directed to polymeric-prodrug transport forms of the formula: 1
    Type: Application
    Filed: August 8, 2003
    Publication date: March 18, 2004
    Inventors: Anthony J. Martinez, Annapurna Pendri, Richard B. Greenwald, Yun H. Choe
  • Patent number: 6706740
    Abstract: Heterocyclic aromatic amides (HAA) according to Formula I: wherein X1-X4, M, Z, and A are herein defined. The invention also encompasses hydrates, salts and complexes thereof. These compounds are useful as antifungal agents.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: March 16, 2004
    Assignee: Dow AgroSciences LLC
    Inventors: Michael J. Ricks, William H. Dent, III, Richard B. Rogers, Chenglin Yao, Bassam S. Nader, John L. Miesel, Gina M. Fitzpatrick, Kevin G. Meyer, Noormohamed M. Niyaz, Irene M. Morrison, Matthew J. Henry, Jenifer L. Adamski Butz, Robert P. Gajewski
  • Patent number: 6706725
    Abstract: The invention relates to novel bicyclic compounds having the general formula (I): as well as to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, in carcinology and in the field of autoimmune diseases and that of organ or tissue transplants in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: March 16, 2004
    Assignee: Galderma Research & Development, S.N.C.
    Inventor: Jean-Michel Bernardon
  • Patent number: 6706743
    Abstract: The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: March 16, 2004
    Assignee: Pfizer Inc
    Inventors: Robert F. Day, Jennifer A. Lafontaine
  • Patent number: 6706686
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: March 16, 2004
    Assignee: The Regents of the University of Colorado
    Inventors: Carlin Long, Eric N. Olson, Michael Bristow, Timothy A. McKinsey
  • Publication number: 20040048852
    Abstract: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical.
    Type: Application
    Filed: January 7, 2003
    Publication date: March 11, 2004
    Inventors: Thomas E. Barta, Daniel P. Becker, Terri L. Boehm, Gary A. DeCrezcenzo, John N. Freskos, Daniel P. Getman, Joseph J. McDonald, Clara I. Villamil, Louis John Bedell, Jeffery N. Carroll, Theresa R. Fletcher, Susan Landis Hockerman, Stephen A. Kolodziej, Madeleine H. Li, Deborah A. Mischke, Patrick B. Mullins, Carol Pearcy Howard, Joseph Gerace Rico, Nathan W. Stehle
  • Publication number: 20040048897
    Abstract: This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Inventors: Brent McCleland, Michael R. Palovich, Katherine L. Widdowson
  • Publication number: 20040048907
    Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.
    Type: Application
    Filed: May 15, 2003
    Publication date: March 11, 2004
    Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
  • Publication number: 20040048904
    Abstract: Amide compounds of the formula: 1
    Type: Application
    Filed: September 4, 2003
    Publication date: March 11, 2004
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Akira Yamada, Satoshi Aoki
  • Patent number: 6703383
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: March 9, 2004
    Assignee: Sepracor, Inc.
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Patent number: 6703425
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: James Allen Knobelsdorf, Timothy Alan Shepherd, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040043952
    Abstract: The present invention relates, inter alia, to pentaerythritol lipid derivatives that are useful for the intracellular delivery of nucleic acids. Such pentaerythritol lipid derivatives are useful for the preparation of transfection complexes (such as liposomes, lipoplexes, and other lipid vesicles) that can be used to deliver nucleic acids into mammalian cells.
    Type: Application
    Filed: May 30, 2003
    Publication date: March 4, 2004
    Applicant: Genteric, Inc.
    Inventors: Edmund J. Niedzinski, Michael Bennett
  • Publication number: 20040044050
    Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 &ohgr;-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.
    Type: Application
    Filed: June 13, 2003
    Publication date: March 4, 2004
    Inventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten
  • Publication number: 20040044049
    Abstract: Compounds, compositions and methods for altering insulin secretion, particularly in the context of treatment of subjects having, or suspected of being at risk for having, diabetes mellitus.
    Type: Application
    Filed: February 10, 2003
    Publication date: March 4, 2004
    Applicant: MitoKor
    Inventors: Yazhong Pei, Soumitra S. Ghosh, Ian William James
  • Publication number: 20040044051
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 17, 2003
    Publication date: March 4, 2004
    Applicant: Schering Corporation
    Inventors: Joseph A. Kozlowski, Bandarpalle B. Shankar, Neng-Yang Shih, Ling Tong
  • Publication number: 20040044047
    Abstract: &agr;- and &bgr;-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Application
    Filed: July 22, 2002
    Publication date: March 4, 2004
    Applicant: G.D. Searle & Co.
    Inventors: Michael J. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Robert M. Heintz, Deborah E. Bertenshaw
  • Publication number: 20040044048
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral fused heterocyclic amino compounds.
    Type: Application
    Filed: February 4, 2003
    Publication date: March 4, 2004
    Applicant: G.D. Searle & Co.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Publication number: 20040043968
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula I: 1
    Type: Application
    Filed: May 30, 2003
    Publication date: March 4, 2004
    Applicant: Gruenenthal GmbH
    Inventors: Thomas Christoph, Elmar Friderichs
  • Patent number: 6699884
    Abstract: Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more fluoro-substituted benzenesulfonyl compounds corresponding to Formula I: wherein A, X, n, R1, R2, and R3 are as described in the specification, and novel fluoro-substituted benzenesulfonyl compounds within Formula I.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: March 2, 2004
    Assignee: Pharmacia Corporation
    Inventors: David L. Brown, Matthew J. Graneto, Cindy L. Ludwig, John M. Molyneaux, John J. Talley
  • Patent number: 6699893
    Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: March 2, 2004
    Assignee: Pfizer Inc
    Inventors: Robert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
  • Patent number: 6699853
    Abstract: The present invention relates to 4-Haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, Processes for Their Preparation, Compositions Comprising Them, and Their Use as Pesticides More particularly, the present invention relates to 4-trifluoromethyl-3-oxadiazolylpyridines of the formula (I′), to processes for their preparation, to compositions comprising them and to the use of these compounds for controlling animal pests, in particular insects, spider mites, ectoparasites and helminths: wherein X, Y are as defined in the description.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: March 2, 2004
    Assignee: Hoechst Schering AgrEvo GmbH
    Inventors: Sven Harmsen, Henricus Maria Martinus Bastiaans, Wolfgang Schaper, Jörg Tiebes, Uwe Döller, Daniela Jans, Ulrich Sanft, Waltraud Hempel, Maria-Theresia Thönessen, Thomas Taapken, Burkhard Rook, Manfred Kern
  • Patent number: 6699894
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of inflammatory bowel disease.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: March 2, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Keith A. Earle, Hector W. Alila
  • Publication number: 20040039025
    Abstract: A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of disease states in which glycine is involved are disclosed.
    Type: Application
    Filed: August 28, 2003
    Publication date: February 26, 2004
    Inventors: Syed M. Ali, Kurt R. Brunden, Dario Doller, Brian Herbert, Jack B. Jiang, Amy Jordan
  • Publication number: 20040039034
    Abstract: The present invention relates to compounds of formula (I): 1
    Type: Application
    Filed: April 30, 2003
    Publication date: February 26, 2004
    Inventors: John A. Tucker, Brian A. Sherer, Ying Zi Xu, Louis Brogley, Shon R. Pulley, Jon S. Jacobs, James P. Beck, Varghese John
  • Publication number: 20040039033
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts thereof, 1
    Type: Application
    Filed: December 10, 2002
    Publication date: February 26, 2004
    Inventors: Karnail S. Atwal, Gary J. Grover, Charles Z. Ding, Philip D. Stein, John Lloyd, Saleem Ahmad, Lawrence G. Hamann, David Green, Francis N. Ferrara
  • Publication number: 20040038966
    Abstract: A composition for use as an antiobestic agent and preventive or therapeutic agent for diabetes, containing a compound of the formula (I): 1
    Type: Application
    Filed: November 25, 2002
    Publication date: February 26, 2004
    Inventors: Toshisada Yano, Isako Sakaguchi, Goro Katsuura, Naoki Yoshikawa
  • Publication number: 20040039014
    Abstract: The present invention features compounds active at both the serotonin reuptake site and the N-methyl-D-aspartate (NMDA) receptor and the use of such compounds for treating different disorders. Compounds having activity at the serotonin reuptake site and the NMDA receptor (“multi-active compounds”) can be used to treat different types of disorders such as depression, obsessive-compulsive disorders (OCD), sleep, disorders, sexual dysfunction, and eating disorders. Preferably, the multi-active compounds are used to treat depression.
    Type: Application
    Filed: November 21, 2001
    Publication date: February 26, 2004
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Alan L. Mueller, Scott T. Moe, Manuel F. Balandrin
  • Patent number: 6696456
    Abstract: Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where R1, R2, R3, R4, R5, R6, G and Z have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of Formula I, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating metalloprotease-related maladies using the compounds or the pharmaceutical compositions.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: February 24, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Stanislaw Pikul, Norman Eugene Ohler, Kelly Michelle Solinsky, Neil Gregory Almstead, Biswanath De, Michael George Natchus
  • Publication number: 20040033986
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
    Type: Application
    Filed: May 16, 2003
    Publication date: February 19, 2004
    Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, Elena Bogatcheva, Leo Einck
  • Publication number: 20040034071
    Abstract: A thioaryl sulfonamide hydroxamic acid compound that, inter alia, inhibits matrix metalloprotease activity is disclosed, as are a treatment process that comprises administering a contemplated thioaryl sulfonamide hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
    Type: Application
    Filed: January 21, 2003
    Publication date: February 19, 2004
    Inventors: Daniel P. Getman, Daniel P. Becker, Thomas E. Barta, Clara I. Villamil, Susan L. Hockerman, Louis J. Bedell, Madeleine Hui Li, John N. Freskos, Robert M. Heintz, Joseph J. Mc.Donald, Gary A. DeCrescenzo
  • Publication number: 20040034070
    Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.
    Type: Application
    Filed: August 8, 2003
    Publication date: February 19, 2004
    Inventors: Laura Barzaghi, Philippe R. Bovy, Roberto Cecchi, Tiziano Croci, Stefano Romagnano
  • Publication number: 20040034024
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Application
    Filed: November 5, 2002
    Publication date: February 19, 2004
    Inventors: Kelly M Aubart, Siegfried B Christensen, Jacques Briand, Maxwell David Cummings
  • Patent number: 6693123
    Abstract: Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally subs
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: February 17, 2004
    Assignee: University of Pittsburgh
    Inventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Greg B. Donner, Stephen A. Fakhoury, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Bruce G. Szczepankiewicz, Indrani W. Gunawardana
  • Publication number: 20040029933
    Abstract: Substituted phenylacetic acids, phenylethanols and related compounds are provided that are useful in treating or controlling a number of diseases associated with glucose metabolism, lipid metabolism and insulin secretion.
    Type: Application
    Filed: March 19, 2003
    Publication date: February 12, 2004
    Applicant: Metabolex, Inc.
    Inventors: Zuchun Zhao, Xin Chen, Jianchao Wang, Hongbin Sun, Jack Shih-Chieh Liang
  • Publication number: 20040029932
    Abstract: Compounds of Formula (IA) and Formula (IB) 1
    Type: Application
    Filed: March 21, 2003
    Publication date: February 12, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Mario G. Cardozo, Christian Hanke Justus Joachim Harcken, Thomas M. Kirrane, Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
  • Publication number: 20040029878
    Abstract: A pharmaceutical composition comprising an effective amount of a compound of formula I 1
    Type: Application
    Filed: May 30, 2003
    Publication date: February 12, 2004
    Applicant: Gruenenthal GmbH
    Inventors: Thomas Christoph, Elmar Friderichs